trans-2,3,5-trimethyl-6-(3',7',11',15'-tetramethyl-2',6',10',14'-hexadecatetraenyl)-1,4-benzoquinone | 66958-66-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: trans-2,3,5-trimethyl-6-(3',7',11',15'-tetramethyl-2',6',10',14'-hexadecatetraenyl)-1,4-benzoquinone
• 英文别名: 2,3,5-trimethyl-6-((2E,6E,10E)-3,7,11,15-tetramethyl-hexadeca-2,6,10,14-tetraenyl)-[1,4]benzoquinone；2,3,5-trimethyl-6-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]cyclohexa-2,5-diene-1,4-dione
• CAS: 66958-66-5
• 化学式: C₂₉H₄₂O₂
• 分子量: 422.651
• InChiKey: KHPYPLZSOFOUNC-INVBOZNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.7
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-chloromethyl-2,5-dimethoxy-3,4,6-trimethyl-benzene 在 bis(triphenylphosphine)nickel(II) chloride 、 正丁基锂 、 二氯二茂锆 、 ammonium cerium(IV) nitrate 、 三苯基膦 作用下， 以 水 、 乙腈 为溶剂， 反应 1.5h， 生成 trans-2,3,5-trimethyl-6-(3',7',11',15'-tetramethyl-2',6',10',14'-hexadecatetraenyl)-1,4-benzoquinone
  参考文献：
  名称：

  利用Ni（0）催化快速获得CoQ n，维生素K 1和K 2以及相关的烯丙基对苯二酚的途径

  摘要：

  催化量的Ni（0）介导的乙烯基丙氨酸与氯甲基化对醌之间的偶联反应直接导致烯丙基化产物，包括辅酶Q以及维生素K 1和K 2。

  DOI：

  10.1016/s0040-4020(97)10222-8

文献信息

• Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
  申请人：Miller M. Guy

  公开号：US20060281809A1

  公开（公告）日：2006-12-14

  Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

  披露了治疗或抑制线粒体疾病的方法，如弗里德赖希共济失调（FRDA）、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、卒中（MELAS）或科恩斯-赛尔综合征（KSS），以及在本发明方法中有用的化合物，如α-生育酚醌。还披露了用于治疗其他疾病的方法和化合物。还披露了用于评估受试者代谢状态和治疗效果的能量生物标志物。还披露了调节、正常化或增强能量生物标志物的方法，以及用于这些方法的化合物。
• REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
  申请人：Miller Guy M.

  公开号：US20100222436A1

  公开（公告）日：2010-09-02

  Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

  本发明揭示了治疗或抑制线粒体疾病的方法，如弗里德雷希共济失调症（FRDA）、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）或柯恩斯-萨耶综合症（KSS），以及在所述方法中有用的化合物，如α-生育酚醌。本发明还揭示了用于治疗其他疾病的方法和化合物。还揭示了有用于评估受试者代谢状态和治疗效果的能量生物标志物。本发明还揭示了调节、规范或增强能量生物标志物的方法，以及用于此类方法的化合物。
• Redox-active Therapeutics For Treatment Of Mitochondrial Diseases And Other Conditions And Modulation Of Energy Biomarkers
  申请人：Edison Pharmaceuticals, Inc.

  公开号：EP2471530A1

  公开（公告）日：2012-07-04

  Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

  本发明公开了治疗或抑制线粒体疾病的方法，如弗里德雷希共济失调（FRDA）、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）或卡恩斯-赛尔综合征（KSS），以及用于本发明方法的化合物，如α-生育酚醌。本发明还公开了用于治疗其他疾病的方法和化合物。本发明还公开了用于评估受试者代谢状态和治疗效果的能量生物标志物。还公开了调节、正常化或增强能量生物标志物的方法，以及用于此类方法的化合物。
• Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
  申请人：Miller Guy M.

  公开号：US10039722B2

  公开（公告）日：2018-08-07

  Methods of treating or suppressing oxidative stress diseases and symptoms related to oxidative stress affecting normal electron flow in the cells or caused by reactive oxygen species with redox-active therapeutics. Use of redox-active therapeutics for the reduction, suppression or treatment of oxidative stress induced by chemical agents such as contrast agents and other nephrotoxic agents, by radiation exposure, and by disruptions in the transport of oxygen to tissues, is disclosed.

  用氧化还原活性疗法治疗或抑制氧化应激性疾病以及与影响细胞内正常电子流的氧化应激或活性氧引起的氧化应激有关的症状的方法。本发明公开了利用氧化还原活性疗法减少、抑制或治疗由化学制剂（如造影剂和其他肾毒性制剂）、辐射照射以及氧向组织的运输中断引起的氧化应激。
• Treatment of pervasive developmental disorders with redox-active therapeutics
  申请人：BioElectron Technology Corporation

  公开号：US10105325B2

  公开（公告）日：2018-10-23

  Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

  治疗或抑制广泛性发育障碍（PDDs）的方法，包括自闭症、阿斯伯格综合症、儿童分裂症（CDD）、雷特氏症、未另作指定的发育障碍（PDD-NOS）或注意缺陷/多动障碍（ADHD），包括向有需要的受试者施用治疗有效量的一种或多种本文公开的化合物。